Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO versus METHYLPHENIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO versus METHYLPHENIDATE.
EVEKEO vs METHYLPHENIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
None Documented
None Documented
Clinical Note
moderateDexmethylphenidate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexmethylphenidate."
Clinical Note
moderateBretylium + Methylphenidate
"Bretylium may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateCyamemazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate."
Clinical Note
moderateSulpiride + Methylphenidate
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
Category C
Category A/B
CNS Stimulant
CNS Stimulant
"The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate."